SCYNEXIS, Inc.

NasdaqGM:SCYX 株式レポート

時価総額:US$50.5m

SCYNEXIS 将来の成長

Future 基準チェック /56

SCYNEXISは、49.4%と29.4%でそれぞれ年率49.4%で利益と収益が成長すると予測される一方、EPSはgrowで50%年率。

主要情報

49.4%

収益成長率

50.0%

EPS成長率

Pharmaceuticals 収益成長23.6%
収益成長率29.4%
将来の株主資本利益率n/a
アナリストカバレッジ

Low

最終更新日03 Sep 2024

今後の成長に関する最新情報

SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 12
SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Recent updates

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Aug 08
Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop

Jun 19
Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop

SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 12
SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly

Apr 04
SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly

Scynexis: Update Following Restructuring Of GSK Deal

Apr 02

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S

Feb 01
Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S

Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?

Dec 21
Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?

Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding

Sep 26
Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Aug 17
Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Scynexis: Uninvestible At This Point, Downgrading To A Sell Rating

Aug 26

SCYNEXIS Q2 2022 Earnings Preview

Aug 12

FDA accepts Scynexis' application to expand label for vaginal yeast infections treatment

Aug 01

SCYNEXIS gains after favorable data for antifungal agent in new indication

Jul 19

SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially

Apr 07
SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially

SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying

Mar 07

Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates

Feb 13
Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates

Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?

Dec 03
Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?

Scynexis: Leading The Yeast Infection Treatment Industry

Jul 27

Scynexis' Brexafemme qualifies for 10 years of exclusivity for vaginal yeast infections

Jun 09

FDA approves SCYNEXIS' BREXAFEMME vaginal yeast infections treatment

Jun 02

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Apr 13
Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Market Sentiment Around Loss-Making SCYNEXIS, Inc. (NASDAQ:SCYX)

Mar 15
Market Sentiment Around Loss-Making SCYNEXIS, Inc. (NASDAQ:SCYX)

業績と収益の成長予測

NasdaqGM:SCYX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/20261116719424
12/31/2025517-2844
12/31/202417-21N/A-324
6/30/202410-35-10-10N/A
3/31/20241401017575N/A
12/31/2023140676060N/A
9/30/2023136724545N/A
6/30/2023136441010N/A
3/31/20236-91-83-83N/A
12/31/20225-63-80-80N/A
9/30/20224-78-83-83N/A
6/30/20223-49-78-77N/A
3/31/20222-34-71-70N/A
12/31/202113-33-56-55N/A
9/30/202113-46-46-46N/A
6/30/202112-45-39-39N/A
3/31/202112-53-36-36N/A
12/31/2020N/A-55-49-49N/A
9/30/2020N/A-27-46-46N/A
6/30/2020N/A-36-47-47N/A
3/31/20200-38-46-46N/A
12/31/20190-54-38-38N/A
9/30/20190-37-31-31N/A
6/30/20190-29-27-26N/A
3/31/20190-31-27-27N/A
12/31/20180-12-29-28N/A
9/30/20180-22-28-27N/A
6/30/20180-31-27-27N/A
3/31/20180-24N/A-26N/A
12/31/20170-25N/A-25N/A
9/30/20170-21N/A-24N/A
6/30/20170-24N/A-26N/A
3/31/20170-28N/A-27N/A
12/31/20160-30N/A-29N/A
9/30/20160-35N/A-31N/A
6/30/20160-31N/A-30N/A
3/31/20160-30N/A-29N/A
12/31/20150-28N/A-25N/A
9/30/20151-23N/A-20N/A
6/30/20151-19N/A-18N/A
3/31/20151-11N/A-14N/A
12/31/20141-7N/A-9N/A
9/30/20144-42N/A-9N/A
6/30/20148-43N/A-6N/A
3/31/201412-47N/A-2N/A
12/31/201317-47N/A-4N/A

アナリストによる今後の成長予測

収入対貯蓄率: SCYXは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 2.5% ) よりも高い成長率であると考えられます。

収益対市場: SCYX今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: SCYX今後 3 年以内に収益を上げることが予想されます。

収益対市場: SCYXの収益 ( 29.4% ) US市場 ( 8.8% ) よりも速いペースで成長すると予測されています。

高い収益成長: SCYXの収益 ( 29.4% ) 20%よりも速いペースで成長すると予測されています。


一株当たり利益成長率予想


将来の株主資本利益率

将来のROE: SCYXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です


成長企業の発掘